ValuEngine cut shares of Regenxbio (NASDAQ:RGNX) from a buy rating to a hold rating in a research report report published on Wednesday morning.
Other analysts also recently issued reports about the stock. Barclays boosted their target price on shares of Regenxbio from $48.00 to $83.00 and gave the stock an overweight rating in a report on Monday, August 13th. Raymond James restated a buy rating on shares of Regenxbio in a report on Monday, October 29th. BidaskClub downgraded shares of Regenxbio from a buy rating to a hold rating in a report on Friday, October 5th. Chardan Capital reduced their target price on shares of Regenxbio from $130.00 to $127.50 and set a buy rating on the stock in a report on Wednesday, August 8th. Finally, TheStreet upgraded shares of Regenxbio from a d+ rating to a c rating in a report on Monday, September 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. Regenxbio has a consensus rating of Hold and a consensus price target of $77.81.
Regenxbio stock opened at $52.44 on Wednesday. Regenxbio has a twelve month low of $23.25 and a twelve month high of $85.10. The stock has a market capitalization of $2.01 billion, a PE ratio of 27.00, a price-to-earnings-growth ratio of 8.29 and a beta of -0.53.
In related news, CEO Kenneth T. Mills sold 7,510 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $59.35, for a total transaction of $445,718.50. Following the transaction, the chief executive officer now directly owns 331,710 shares in the company, valued at approximately $19,686,988.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Vittal Vasista sold 7,500 shares of the company’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $74.86, for a total transaction of $561,450.00. Following the transaction, the chief financial officer now owns 120,722 shares in the company, valued at $9,037,248.92. The disclosure for this sale can be found here. Insiders have sold a total of 448,954 shares of company stock worth $28,902,916 over the last quarter. 16.90% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. Meadow Creek Investment Management LLC bought a new position in Regenxbio during the 2nd quarter valued at about $141,000. Riverhead Capital Management LLC grew its holdings in Regenxbio by 137.5% during the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,100 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Regenxbio during the 2nd quarter valued at about $157,000. Glen Harbor Capital Management LLC purchased a new stake in Regenxbio in the 2nd quarter valued at about $171,000. Finally, SG Americas Securities LLC purchased a new stake in Regenxbio in the 2nd quarter valued at about $179,000. Institutional investors own 79.08% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.